抑制流体I类HDAC抑制胰腺癌的进展
bioRxiv : the preprint server for biology
|September 25, 2023
概括
基因组脱乙酶 (HDACs) 驱动胰腺癌.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
- 瘤微环境 瘤微环境
背景情况:
- 胰腺管道腺癌 (PDAC) 具有促进治疗耐药性的脱塑性瘤微环境 (TME).
- 瘤性病变会操纵树叶表观遗传机制,从而产生这种耐药的TME.
研究的目的:
- 鉴定胰腺 stromal 纤维细胞中的关键表观遗传因素,驱动亲脱塑性和亲瘤源的程序.
- 研究针对PDAC中的这些表观遗传因素的治疗潜力.
主要方法:
- 在胰腺 stromal 纤维细胞中研究的 I 类 histone deacetylases (HDACs).
- 在癌症相关纤维细胞 (CAFs) 中利用HDAC枯竭和在PDAC小鼠模型中使用肠静止剂 (Ent) 治疗.
- 分析了染色体结构的变化和基因表达 (SRF,FOXM1,LIF).
主要成果:
- 第I类HDACs通过SRF和FOXM1.1诱导了亲可塑性和亲瘤性转录程序.
- 通过LIF表达,HDACs通过LIF表达促进了亲瘤的交叉交叉.
- 在PDAC模型中,HDAC抑制 (HDACi) 降低了脑膜激活和瘤进展.
- 在PDAC流体内,HDACi丰富了脂原性纤维细胞亚群.
结论:
- 第I类HDACs是PDAC流体的关键表观遗传调节者.
- 通过向HDACs的抑制剂,如氨酸,通过调节肌体活化和纤维细胞群体来显示治疗潜力.
- 抑制HDAC是一种有前途的表观遗传策略,用于PDAC治疗.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K


